United Therapeutics Corporation
UTHRUnited Therapeutics Corporation is an American biotechnology company that develops pharmaceuticals and technologies related to organ transplantation, including xenotransplantation. Many of the company's products are focused towards lung disease and organ manufacturing. United Therapeutics is co-headquartered in Silver Spring, Maryland and Research Triangle Park, North Carolina, with additional facilities in Magog and Bromont, Quebec; Melbourne and Jacksonville, Florida; Blacksburg, Virginia; and Manchester, New Hampshire.
Drugs in Pipeline
22
Phase 3 Programs
12
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 0 past
No catalysts found.
Inhaled Treprostinil
Progressive Pulmonary Fibrosis
Treprostinil Diolamine
Pulmonary Arterial Hypertension
Ralinepag
Pulmonary Arterial Hypertension
UT-15
Pulmonary Hypertension
oral treprostinil
PAH
UT-15C SR
Pulmonary Hypertension
UT-15C (treprostinil diolamine)
Pulmonary Arterial Hypertension
Dinutuximab
Small Cell Lung Cancer
Oral treprostinil (UT-15C) Sustained Release Tablets
Pulmonary Hypertension
treprostinil diethanolamine
Pulmonary Arterial Hypertension
UI05MSP015CT
Functional Dyspepsia
KALOMIN™ Tab.
Acute Bronchitis
Semaglutide Injection (Ozempic®)
Type 2 Diabetes Mellitus (T2DM)
GGTA1 KO Thymokidney
ESRD (End-Stage Renal Disease)
APD811
Pulmonary Arterial Hypertension
UB-311
Alzheimer's Disease
UT-15C
Pulmonary Hypertension
Tyvaso Inhalation Solution
Pulmonary Arterial Hypertension
ch14.18 -NCI
Neuroblastoma
Antibody UB-421
HIV-1 Infection in Adults
UBT251
Metabolic Dysfunction-associated Steatohepatitis (MASH)
10 GE Xenokidney
ESRD (End-Stage Renal Disease)
| Drug Name | Phase | Indication | Designations |
|---|---|---|---|
Inhaled Treprostinil | Phase 3 | Progressive Pulmonary Fibrosis | - |
Treprostinil Diolamine | Phase 3 | Pulmonary Arterial Hypertension | - |
Ralinepag | Phase 3 | Pulmonary Arterial Hypertension | - |
UT-15 | Phase 3 | Pulmonary Hypertension | - |
oral treprostinil | Phase 3 | PAH | - |
UT-15C SR | Phase 3 | Pulmonary Hypertension | - |
UT-15C (treprostinil diolamine) | Phase 3 | Pulmonary Arterial Hypertension | - |
Dinutuximab | Phase 3 | Small Cell Lung Cancer | - |
Oral treprostinil (UT-15C) Sustained Release Tablets | Phase 3 | Pulmonary Hypertension | - |
treprostinil diethanolamine | Phase 3 | Pulmonary Arterial Hypertension | - |
UI05MSP015CT | Phase 3 | Functional Dyspepsia | - |
KALOMIN™ Tab. | Phase 3 | Acute Bronchitis | - |
Semaglutide Injection (Ozempic®) | Phase 2 | Type 2 Diabetes Mellitus (T2DM) | - |
GGTA1 KO Thymokidney | Phase 2 | ESRD (End-Stage Renal Disease) | - |
APD811 | Phase 2 | Pulmonary Arterial Hypertension | - |
UB-311 | Phase 2 | Alzheimer's Disease | - |
UT-15C | Phase 2 | Pulmonary Hypertension | - |
Tyvaso Inhalation Solution | Phase 2 | Pulmonary Arterial Hypertension | - |
ch14.18 -NCI | Phase 2 | Neuroblastoma | - |
Antibody UB-421 | Phase 2 | HIV-1 Infection in Adults | - |
UBT251 | Phase 2 | Metabolic Dysfunction-associated Steatohepatitis (MASH) | - |
10 GE Xenokidney | Phase 2 | ESRD (End-Stage Renal Disease) | - |